The initiation and prevention of multiple sclerosis

Nature Reviews Neurology

Volumn 8, Issue 11, 2012, Pages 602-612

  Ascherio, Alberto ^a   Munger, Kassandra L ^a   Lünemann, Jan D ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; EPSTEIN BARR VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; VITAMIN D;

AGE DISTRIBUTION; ALLELE; ANTIBODY PRODUCTION; ANTIBODY TITER; B LYMPHOCYTE; CANCER RISK; CELL DIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; CYP27B1 GENE; DEMYELINATING DISEASE; DIET; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; EVIDENCE BASED PRACTICE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RESISTANCE; GENETIC RISK; GEOGRAPHIC DISTRIBUTION; HEREDITY; HERITABILITY; HETEROZYGOTE; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; LIFESTYLE; LIVER CANCER; MEDICAL RESEARCH; MIGRATION; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NUTRITIONAL STATUS; PRIORITY JOURNAL; PUBLIC HEALTH; RADIATION EXPOSURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; SMOKING CESSATION; THERAPY EFFECT; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

ANIMALS; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; MULTIPLE SCLEROSIS; RISK FACTORS; SMOKING; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84868535570     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.198     Document Type: Review

References (146)

1. MacMahon, B. & Trichopoulos, D. Epidemiology: Principles and Methods, 2nd edn (Little, Brown & Co, Boston, 1996).
2. Czeizel, A. E. & Dudas, I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 327, 1832-1835 (1992). (Pubitemid 23003073)
3. Dwyer, T., Ponsonby, A. L., Blizzard, L., Newman, N. M. & Cochrane, J. A. The contribution of changes in the prevalence of prone sleeping position to the decline in sudden infant death syndrome in Tasmania. JAMA 273, 783-789 (1995).
4. McMahon, B. J. et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54, 801-807 (2011).
5. Koch-Henriksen, N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult. Scler. 5, 293-296 (1999). (Pubitemid 29405629)
6. Mayr, W. T. et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 61, 1373-1377 (2003). (Pubitemid 37463373)
7. Compston, A. & Coles, A. Multiple sclerosis. Lancet 359, 1221-1231 (2002). (Pubitemid 34304266)
8. Kurtzke, J. F., Beebe, G. W. & Norman, J. E. Epidemiology of multiple sclerosis in US veterans:1. Race, sex, and geographic distribution. Neurology 29, 1228-1235 (1979). (Pubitemid 9231587)
9. Wallin, M. T., Page, W. F. & Kurtzke, J. F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol. 55, 65-71 (2004). (Pubitemid 38067362)
10. Wallin, M. T. et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 135, 1778-1785 (2012).
11. Hansen, T. et al. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult. Scler. 11, 504-510 (2005). (Pubitemid 41387692)
12. Willer, C. J., Dyment, D. A., Risch, N. J., Sadovnick, A. D. & Ebers, G. C. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl Acad. Sci. USA 100, 12877-12882 (2003). (Pubitemid 37339993)
13. Ebers, G. C., Sadovnick, A. D. & Risch, N. J. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 377, 150-151 (1995).
14. Schmidt, H., Williamson, D. & Ashley-Koch, A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am. J. Epidemiol. 165, 1097-1109 (2007). (Pubitemid 47233710)
15. Sadovnick, A. D. Genetic background of multiple sclerosis. Autoimmun. Rev. 11, 163-166 (2012).
16. Marrosu, M. G. et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am. J. Hum. Genet. 61, 454-457 (1997). (Pubitemid 27382324)
17. Haines, J. L. et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum. Mol. Genet. 7, 1229-1234 (1998). (Pubitemid 28383054)
18. Lincoln, M. R. et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc. Natl Acad. Sci. USA 106, 7542-7547 (2009).
19. Patsopoulos, N. A. & de Bakker, P. I. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann. Neurol. 70, 897-912 (2011).
20. Ramagopalan, S. V. et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann. Neurol. 70, 881-886 (2011).
21. Alonso, A., Hernán, M. A. & Ascherio, A. Allergy, family history of autoimmune diseases, and the risk of multiple sclerosis. Acta Neurol. Scand. 117, 15-20 (2008). (Pubitemid 350264499)
22. Zorzon, M. et al. Risk factors of multiple sclerosis: a caseYcontrol study. Neurol. Sci. 24, 242-247 (2003). (Pubitemid 37493179)
23. Acheson, E. D., Bachrach, C. A. & Wright, F. M. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr. Scand. 147, 132-147 (1960).
24. Gale, C. R. & Martyn, C. N. Migrant studies in multiple sclerosis. Prog. Neurobiol. 47, 425-448 (1995). (Pubitemid 26022928)
25. McLeod, J. G., Hammond, S. R. & Kurtzke, J. F. Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration. J. Neurol. 258, 1140-1149 (2011).
26. Kurtzke, J. F., Beebe, G. W. & Norman, J. E. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology 35, 672-678 (1985). (Pubitemid 15067020)
27. Elian, M. & Dean, G. Motor neuron disease and multiple sclerosis among immigrants to England from the Indian subcontinent, the Caribbean, and East and West Africa. J. Neurol. Neurosurg. Psychiatry 56, 454-457 (1993). (Pubitemid 23171771)
28. Cabre, P. et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 128, 2899-2910 (2005). (Pubitemid 41746643)
29. Hernán, M. A., Olek, M. J. & Ascherio, A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 53, 1711-1718 (1999). (Pubitemid 29530344)
30. Koch-Henriksen, N. & Sorensen, P. S. Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere? J. Neurol. Sci. 311, 58-63 (2011).
31. Alonso, A. & Hernán, M. A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71, 129-135 (2008).
32. Simpson, S. Jr, Blizzard, L., Otahal, P., Van der Mei, I. & Taylor, B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 82, 1132-1141 (2011).
33. Taylor, B. V. et al. Latitudinal variation in incidence and type of first central nervous system demyelinating events. Mult. Scler. 16, 398-405 (2010).
34. Henle, W. & Henle, G. in The EpsteinYBarr Virus (eds Epstein, M. A. & Achong, B. G.) 61-78 (Springer, Berlin Heidelberg, New York, 1979).
35. Takeuchi, K. et al. Prevalence of EpsteinYBarr virus in Japan: trends and future prediction. Pathol. Int. 56, 112-116 (2006).
36. Hallee, T. J., Evans, A. S., Niederman, J. C., Brooks, C. M. & Voegtly, J. H. Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years. Yale J. Biol. Med. 3, 182-195 (1974).
37. Warner, H. B. & Carp, R. I. Multiple sclerosis and EpsteinYBarr virus. Lancet 2, 1290 (1981).
38. Thacker, E. L., Mirzaei, F. & Ascherio, A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59, 499-503 (2006). (Pubitemid 43358070)
39. Bach, J. F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347, 911-920 (2002).
40. Ascherio, A. & Munch, M. Epstein-Barr virus and multiple sclerosis. Epidemiology 11, 220-224 (2000). (Pubitemid 30112026)
41. Ascherio, A. & Munger, K. L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61, 288-299 (2007). (Pubitemid 46676728)
42. Alotaibi, S., Kennedy, J., Tellier, R., Stephens, D. & Banwell, B. EpsteinYBarr virus in pediatric multiple sclerosis. JAMA 291, 1875-1879 (2004). (Pubitemid 38509501)
43. Pohl, D. et al. High seroprevalence of EpsteinYBarr virus in children with multiple sclerosis. Neurology 67, 2063-2065 (2006). (Pubitemid 44967394)
44. Banwell, B. et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 6, 773-781 (2007). (Pubitemid 47238663)
45. Levin, L. I., Munger, K. L., O'Reilly, E. J., Falk, K. I. & Ascherio, A. Primary infection with the EpsteinYBarr virus and risk of multiple sclerosis. Ann. Neurol. 67, 824-830 (2010).
46. Beasley, R. P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61, 1942-1956 (1988).
47. Ascherio, A. et al. EpsteinYbarr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286, 3083-3088 (2001). (Pubitemid 34016522)
48. Levin, L. I. et al. Temporal relationship between elevation of EpsteinYBarr virus antibody titres and initial onset of neurological symptoms in multiple sclerosis. JAMA 293, 2496-2500 (2005). (Pubitemid 40705731)
49. Sundström, P. et al. An altered immune response to EpsteinYBarr virus in multiple sclerosis: a prospective study. Neurology 62, 2277-2282 (2004). (Pubitemid 38787787)
50. DeLorenze, G. N. et al. EpsteinYBarr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 63, 839-844 (2006). (Pubitemid 43882291)
51. Munger, K. L., Levin, L. I., O'Reilly, E. J., Falk, K. I. & Ascherio, A. Anti EpsteinYBarr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult. Scler. 17, 1185-1193 (2011).
52. Simon, K. C., Saghafian-Hedengren, S., Sverremark-Ekström, E., Nilsson, C. & Ascherio, A. Age at EpsteinYBarr virus infection and EpsteinYBarr virus nuclear antigen 1 antibodies in Swedish children. Mult. Scler. Relat. Disord. 1, 136-138 (2012).
53. Lünemann, J D. & Munz, C. EBV in MS: guilty by association? Trends Immunol. 30, 243-248 (2009).
54. Lovett-Racke, A. E. et al. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest. 101, 725-730 (1998). (Pubitemid 28096067)
55. Markovic-Plese, S., Cortese, I., Wandinger, K. P., McFarland, H. F. & Martin, R. CD4+CD28Y costimulation-independent T cells in multiple sclerosis. J. Clin. Invest. 108, 1185-1194 (2001). (Pubitemid 32995377)
56. Viglietta, V., Baecher-Allan, C., Weiner, H. L. & Hafler, D. A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971-979 (2004). (Pubitemid 38481088)
57. Lünemann, J. D. et al. Increased frequency and broadened specificity of latent EBV nuclear antigen 1 specific T cells in multiple sclerosis. Brain 129, 1493-1506 (2006). (Pubitemid 43999382)
58. Munz, C. et al. Human CD4+ T lymphocytes consistently respond to the latent EpsteinYBarr virus nuclear antigen EBNA1. J. Exp. Med. 191, 1649-1660 (2000). (Pubitemid 30331564)
59. Lünemann, J. D. et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL 2. J. Exp. Med. 205, 1763-1773 (2008).
60. Hauser, S. L. et al. B cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008). (Pubitemid 351240747)
61. Thorley-Lawson, D. A. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1, 75-82 (2001). (Pubitemid 33741978)
62. Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405-411 (1998). (Pubitemid 28462761)
63. Pender, M. P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 24, 584-588 (2003). (Pubitemid 37338526)
64. Lassmann, H., Niedobitek, G., Aloisi, F. & Middeldorp, J. M. EpsteinYBarr virus in the multiple sclerosis brain: a controversial issue - report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 134, 2772-2786 (2011).
65. Tzartos, J. S. et al. Association of innate immune activation with latent EpsteinYBarr virus in active MS lesions. Neurology 78, 15-23 (2012).
66. Munz, C., Lünemann, J. D., Getts, M. T. & Miller, S. D. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat. Rev. Immunol. 9, 246-258 (2009).
67. Salmi, A. A., Panelius, M., Halonen, P., Rinne, U. K. & Penttinen, K. Measles virus antibody in cerebrospinal fluids from patients with multiple sclerosis. Br. Med. J. 1, 477-479 (1972).
68. Vartdal, F., Vandvik, B. & Norrby, E. Viral and bacterial antibody responses in multiple sclerosis. Ann. Neurol. 8, 248-255 (1980). (Pubitemid 10018372)
69. Derfuss, T., Hohlfeld, R. & Meinl, E. Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B cell response. J. Neurol. 252, 986-971 (2005).
70. Jacobi, C., Lange, P. & Reiber, H. Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: discrimination between microorganism-driven and polyspecific immune response. J. Neuroimmunol. 187, 139-146 (2007). (Pubitemid 47001538)
71. Jarius, S. et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 79, 1134-1136 (2008).
72. Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an EpsteinYBarr virus vaccine in healthy young adults. J. Infect. Dis. 196, 1749-1753 (2007). (Pubitemid 351411934)
73. Lycke, J. et al. Acyclovir treatment of relapsingYremitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J. Neurol. 243, 214-224 (1996).
74. Friedman, J. E. et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult. Scler. 11, 286-295 (2005). (Pubitemid 40775184)
75. Lünemann, J. D. et al. Elevated EpsteinYBarr virus-encoded nuclear antigen 1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 67, 159-169 (2010).
76. van der Mei, I. A., Ponsonby, A. L., Blizzard, L. & Dwyer, T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20, 168-174 (2001). (Pubitemid 32718873)
77. Ebers, G. C. Environmental factors and multiple sclerosis. Lancet Neurol. 7, 268-277 (2008). (Pubitemid 351222732)
78. Handel, A. E., Giovannoni, G., Ebers, G. C. & Ramagopalan, S. V. Environmental factors and their timing in adult-onset multiple sclerosis. Nat. Rev. Neurol. 6, 156-166 (2010).
79. Swank, R. L., Lerstad, O., Strøm, A. & Backer, J. Multiple sclerosis in rural Norway. Its geographic and occupational incidence in relation to nutrition. N. Engl. J. Med. 246, 721-728 (1952).
80. Antonovsky, A. et al. Epidemiologic study of multiple sclerosis in Israel. Arch. Neurol. 13, 183-193 (1965).
81. Cendrowski, W. et al. Epidemiological study of multiple sclerosis in Western Poland. Eur. Neurol. 2, 90-108 (1969).
82. van der Mei, I. A. et al. Past exposure to sun, skin phenotype and risk of multiple sclerosis: a caseYcontrol study. BMJ 327, 316-321 (2003).
83. Kampman, M. T., Wilsgaard, T. & Mellgren, S. I. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J. Neurol. 254, 471-477 (2007). (Pubitemid 46786722)
84. Munger, K. L. et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62, 60-65 (2004). (Pubitemid 38082871)
85. Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S. & Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832-2838 (2006). (Pubitemid 44969183)
86. Lucas, R. M. et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 76, 540-548 (2011).
87. Ascherio, A., Munger, K. L. & Simon, K. C. Vitamin D and multiple sclerosis. Lancet Neurol. 9, 599-612 (2010).
88. Feskanich, D., Willett, W. C. & Colditz, G. A. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am. J. Clin. Nutr. 77, 504-511 (2003). (Pubitemid 36133396)
89. Hollis, B. W. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J. Nutr. 135, 317-322 (2005). (Pubitemid 40194499)
90. Bischoff-Ferrari, H. A., Giovannucci, E., Willett, W. C., Dietrich, T. & Dawson-Hughes, B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84, 18-28 (2006). (Pubitemid 44699167)
91. Yetley, E. A. Assessing the vitamin D status of the US population. Am. J. Clin. Nutr. 88, 558SY564S (2008).
92. Looker, A. C. et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am. J. Clin. Nutr. 88, 1519-1527 (2008).
93. Gozdzik, A. et al. Low wintertime vitamin D levels in a sample of healthy young adults of diverse ancestry living in the Toronto area: associations with vitamin D intake and skin pigmentation. BMC Public Health 8, 336 (2008).
94. Gonzalez-Gross, M. et al. Vitamin D status among adolescents in Europe: the Healthy Lifestyle in Europe by Nutrition in Adolescence study. Br. J. Nutr. 107, 755-764 (2012).
95. Ascherio, A. & Marrie, R. A. Vitamin D in MS: a vitamin for 4 seasons. Neurology 79, 208-210 (2012).
96. Lucas, R. M. & Ponsonby, A. L. Considering the potential benefits as well as adverse effects of sun exposure: can all the potential benefits be provided by oral vitamin D supplementation? Prog. Biophys. Mol. Biol. 92, 140-149 (2006). (Pubitemid 43831953)
97. Sundqvist, E. et al. Confirmation of association between multiple sclerosis and CYP27B1. Eur. J. Hum. Genet. 18, 1349-1352 (2010).
98. Simon, K. C. et al. Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J. Neurol. 258, 1676-1682 (2011).
99. Wang, J. T. et al. Genetics of vitamin D 1α-hydroxylase deficiency in 17 families. Am. J. Hum. Genet. 63, 1694-1702 (1998). (Pubitemid 30415732)
100. Torkildsen, Ø., Knappskog, P. M., Nyland, H. I. & Myhr, K. M. Vitamin D dependent rickets as a possible risk factor for multiple sclerosis. Arch. Neurol. 65, 809-811 (2008). (Pubitemid 351831460)
101. Munger, K. L., Chitnis, T. & Ascherio, A. Body size and risk of MS in two cohorts of US women. Neurology 73, 1543-1550 (2009).
102. Hedström, A. K., Olsson, T. & Alfredsson, L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult. Scler. 18, 1334-1336 (2012).
103. Mirzaei, F. et al. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann. Neurol. 70, 30-40 (2011).
104. Willer, C. J. et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ 330, 120 (2005).
105. Staples, J., Ponsonby, A. L. & Lim, L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ 340, c1640.
106. Bock, G. et al. The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial. Diabetes Metab. Res. Rev. 27, 942-945 (2011).
107. Mahon, B. D., Gordon, S. A., Cruz, J., Cosman, F. & Cantorna, M. T. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 134, 128-132 (2003). (Pubitemid 36050838)
108. Burton, J. M. et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 74, 1852-1859 (2010).
109. Smolders, J. et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS ONE 5, e15235 (2010).
110. Jorde, R. et al. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 50, 175-180 (2010).
111. Schleithoff, S. S. et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 83, 754-759 (2006). (Pubitemid 44713136)
112. Haddad, J. G. & Chyu, K. J. Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J. Clin. Endocrinol. Metab. 33, 992-995 (1971).
113. Better, O. S. et al. in Phosphate and Minerals in Health and Disease (eds Massry, S. G., Ritz, E. & Jahreis, G.) 467-472 (Plenum Press, New York, 1980).
114. Knippenberg, S. et al. Effect of vitamin D3 supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis. Mult. Scler. 17, 1418-1423 (2011).
115. Peelen, E. et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun. Rev. 10, 733-743 (2011).
116. Liu, P. T. et al. Toll-like receptor triggering of a vitamin D mediated human antimicrobial response. Science 311, 1770-1773 (2006).
117. Laaksi, I. et al. An association of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men. Am. J. Clin. Nutr. 86, 714-717 (2007). (Pubitemid 47435839)
118. Ginde, A. A., Mansbach, J. M. & Camargo, C. A. Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 169, 384-390 (2009).
119. Andersen, O., Lygner, P. E., Bergström, T., Andersson, M. & Vahlne, A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J. Neurol. 240, 417-422 (1993). (Pubitemid 23277408)
120. Panitch, H. S. Influence of infection on exacerbations of multiple sclerosis. Ann. Neurol. 36, S25-S28 (1994). (Pubitemid 24220838)
121. Buljevac, D. et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125, 952-960 (2002). (Pubitemid 34464607)
122. Nørgaard, M. et al. Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based caseYcontrol study. Am. J. Epidemiol. 174, 945-948 (2011).
123. Munger, K. L. et al. Pre-clinical serum 25-hydroxyvitamin D levels and risk of type 1 diabetes in a cohort of US military personnel. Am. J. Epidemiol. (in press).
124. Camargo, C. A. Jr et al. Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age. Am. J. Clin. Nutr. 85, 788-795 (2007). (Pubitemid 46393511)
125. Wallace, R. B. et al. Urinary tract stone occurrence in the Women's Health Initiative randomized clinical trial of calcium and vitamin D supplements. Am. J. Clin. Nutr. 94, 270-277 (2011).
126. Heaney, R. P., Davies, K. M., Chen, T. C., Holick, M. F. & Barger-Lux, M. J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 77, 204-210 (2003). (Pubitemid 36015393)
127. Vieth, R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am. J. Clin. Nutr. 69, 842-856 (1999). (Pubitemid 29205056)
128. Ross A. C. et al. for the Institute of Medicine of the National Academies. DRI Dietary Reference Intakes Calcium and Vitamin D (The National Academies Press, Washington, DC, 2011).
129. Hernán, M. A., Olek, M. J. & Ascherio, A. Cigarette smoking and incidence of multiple sclerosis. Am. J. Epidemiol. 154, 69-74 (2001). (Pubitemid 32565688)
130. Hernán, M. A. et al. Cigarette smoking and the progression of multiple sclerosis. Brain 128, 1461-1465 (2005). (Pubitemid 40826198)
131. Villard-Mackintosh, L. & Vessey, M. P. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception 47, 161-168 (1993). (Pubitemid 23062255)
132. Thorogood, M. & Hannaford, P. C. The influence of oral contraceptives on the risk of mulitple sclerosis. Br. J. Obstet. Gynaecol. 105, 1296-1299 (1998). (Pubitemid 29002831)
133. Hedström, A. K., Bäärnhielm, M., Olsson, T. & Alfredsson, L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 73, 696-701 (2009).
134. Riise, T., Nortvedt, M. W. & Ascherio, A. Smoking is a risk factor for multiple sclerosis. Neurology 61, 1122-1124 (2003). (Pubitemid 37461949)
135. Sundström, P., Nyströom, L. & Hallmans, G. Smoke exposure increases the risk for multiple sclerosis. Eur. J. Neurol. 15, 579-583 (2008). (Pubitemid 351677503)
136. Orton, S. M. et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5, 932-936 (2006).
137. Koch-Henriksen, N. & Sørensen, P. S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 9, 520-532 (2010).
138. Palacios, N., Alonso, A., Bronnum-Hansen, H. & Ascherio, A. Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence. Ann. Epidemiol. 21, 536-542 (2011).
139. Bass, N. H. Pathogenesis of myelin lesions in experimental cyanide encephalopathy. A microchemical study. Neurology 18, 167-177 (1968).
140. Lessell, S. Experimental cyanide optic neuropathy. Arch. Ophthalmol. 86, 194-204 (1971).
141. Chen, J. L. et al. Nicotine raises the influx of permeable solutes across the rat bloodYbrain barrier with little or no capillary recruitment. J. Cereb. Blood Flow Metab. 15, 687-698 (1995).
142. Sopori, M. L. & Kozak, W. Immunomodulatory effects of cigarette smoke. J. Neuroimmunol. 83, 148-156 (1998). (Pubitemid 28280961)
143. Francus, T., Klein, R. F., Staiano-Coico, L., Becker, C. G. & Siskind, G. W. Effects of tobacco glycoprotein (TGP) on the immune system. II. TGP stimulates the proliferation of human T cells and the differentiation of human B cells into Ig secreting cells. J. Immunol. 140, 1823-1829 (1988).
144. Rejdak, K. et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 63, 1439-1445 (2004). (Pubitemid 39426278)
145. Simon, K. C. et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1.*1501 on multiple sclerosis risk. Neurology 74, 1365-1371 (2010).
146. De Jager, P. L. et al. Integrating risk factors: HLA-DRB1.*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 70, 1113-1118 (2008). (Pubitemid 351464768)